Back to Search
MARK JOHANNSEN, MD
MD
Diagnostic Radiology Physician
NPI: 1609812718Individual
Specialties, Licenses & Credentials
Diagnostic Radiology PhysicianPrimary
Radiology — Diagnostic Radiology
Code: 2085R0202X
19406(NE)
Research & Publications (20)
Thermotherapy using magnetic nanoparticles combined with external radiation in an orthotopic rat model of prostate cancer.
PMID 16114060·Prostate·2006
7-preclinical
Phase II trial of weekly paclitaxel and carboplatin chemotherapy in patients with advanced transitional cell cancer.
PMID 15963636·Eur Urol·2005
3-trial
Magnetic fluid hyperthermia (MFH)reduces prostate cancer growth in the orthotopic Dunning R3327 rat model.
PMID 15726645·Prostate·2005
7-preclinical
Native extraction of phosphotyrosine-containing proteins: requirement of tyrosine kinase inhibitors to obtain specific phosphorylation signals.
PMID 10706794·Anal Biochem·2000
7-preclinical
Brain-type and liver-type fatty acid-binding proteins: new tumor markers for renal cancer?
PMID 19622156·BMC Cancer·2009
8-other
Expression of Mcl-1 splicing variants in clear-cell renal cancer and their correlation with histopathological parameters and prognosis.
PMID 19401626·Tumour Biol·2009
8-other
Can tyrosine kinase inhibitors be discontinued in patients with metastatic renal cell carcinoma and a complete response to treatment? A multicentre, retrospective analysis.
PMID 18950936·Eur Urol·2009
4-observational
Organocatalysis with endogenous compounds: towards novel non-enzymatic reactions.
PMID 19364643·Bioorg Med Chem Lett·2009
8-other
Identification of stanniocalcin 2 as prognostic marker in renal cell carcinoma.
PMID 18450365·Eur Urol·2009
1-meta
MicroRNA profiling of clear cell renal cell cancer identifies a robust signature to define renal malignancy.
PMID 19228262·J Cell Mol Med·2009
8-other
Tumoural CXCL16 expression is a novel prognostic marker of longer survival times in renal cell cancer patients.
PMID 19070478·Eur J Cancer·2009
8-other
Down-regulation of the pro-apoptotic XIAP associated factor-1 (XAF1) during progression of clear-cell renal cancer.
PMID 19664236·BMC Cancer·2009
8-other
Claudin-1 protein expression is a prognostic marker of patient survival in renal cell carcinomas.
PMID 18981000·Clin Cancer Res·2008
8-other
Imidazole pyrimidine amides as potent, orally bioavailable cyclin-dependent kinase inhibitors.
PMID 18986805·Bioorg Med Chem Lett·2008
7-preclinical
Energy gain and energy gap in normal-weight children: longitudinal data of the KOPS.
PMID 18379562·Obesity (Silver Spring)·2008
8-other
Plasma matrix metalloproteinase-7 as a metastatic marker and survival predictor in patients with renal cell carcinomas.
PMID 18422740·Cancer Sci·2008
8-other
Serum amyloid A as indicator of distant metastases but not as early tumor marker in patients with renal cell carcinoma.
PMID 18504068·Cancer Lett·2008
8-other
ADAM9 is highly expressed in renal cell cancer and is associated with tumour progression.
PMID 18582378·BMC Cancer·2008
8-other
The FUSE binding proteins FBP1 and FBP3 are potential c-myc regulators in renal, but not in prostate and bladder cancer.
PMID 19087307·BMC Cancer·2008
8-other
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 450 E 23RD ST
FREMONT, NE 68025 - Phone
- (402) 721-3070
Quick Facts
- NPI
- 1609812718
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Not confirmed
- Specialties
- 1
- Locations
- 1
- Publications
- 20
Are you this provider?
Claim Your Profile